Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437496 | 0.92 | ATM (0.49) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL12437487 | 0.90 | PRMT5 (0.46) | PRMT5WDR77MEN1KMT2A | |
| SCHEMBL12437578 | 0.90 | MEN1 (0.55) | PRMT5WDR77ALDH1A1TP53POLB | |
| SCHEMBL12437568 | 0.89 | CYP2D6 (0.51) | PRMT5WDR77ALDH1A1TP53MEN1 | |
| SCHEMBL12437367 | 0.87 | CYP2C19 (0.57) | PRMT5WDR77ALDH1A1TP53POLB | |
| SCHEMBL12437477 | 0.87 | HTT (0.51) | ALDH1A1MEN1KMT2A | |
| SCHEMBL12437392 | 0.85 | KDM4E (0.55) | PRMT5WDR77ALDH1A1POLBMEN1 | |
| SCHEMBL12437569 | 0.85 | KAT6A (0.44) | PRMT5WDR77MEN1KMT2AP2RX7 | |
| SCHEMBL12437481 | 0.84 | ROCK2 (0.48) | PRMT5WDR77ALDH1A1MEN1KMT2A | |
| SCHEMBL12437484 | 0.83 | GAA (0.51) | PRMT5WDR77THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | PRMT5 2072/4885WDR77 1143/4885ALDH1A1 591/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | PRMT5 2072/4885WDR77 1143/4885ALDH1A1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.